ExploreWatchlistsPricing
  1. JP-listed companies
  2. Kyowa Kirin Co.,Ltd.
  3. Financials
  4. Accounts receivable, net

Kyowa Kirin Co.,Ltd. (4151)

Market cap
¥1.3T
P/E ratio
17.2x
Kyowa Kirin manufactures and sells prescription pharmaceuticals through integrated operations from drug development to sales, serving healthcare markets globally.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndAccounts receivable, net (Million JPY)YoY (%)
Dec 31, 2025181,205+15.41%
Dec 31, 2024157,015+31.85%
Dec 31, 2023119,082+6.56%
Dec 31, 2022111,746+7.16%
Dec 31, 2021104,275+12.99%
Dec 31, 202092,287+3.68%
Dec 31, 201989,015-14.77%
Dec 31, 2018104,443+3.41%
Dec 31, 2016100,999-5.46%
Dec 31, 2015106,829-1.87%
Dec 31, 2014108,867

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat